Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study

Innovations in Clinical Neuroscience

Anna I. Guerdjikova¹  Stephanie Williams²  Thomas J. Blom³ 

[1] Drs. Guerdjikova and McElroy and Ms. Mori are with the Lindner Center of HOPE in Mason, Ohio, and the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine in Cincinnati, Ohio.;Mr. Blom is with the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine in Cincinnati, Ohio.;Ms. Williams is with the Cincinnati Childrens Hospital Medical Center in Cincinnati, Ohio.

关键词: obesity;    binge eating;    weight loss;    phentermine-topiramate;    Qsymia®;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine–topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine–topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. The study was registered under the identifier NCT02659475 at ClinicalTrials.gov. Results: Seven participants completed the study. Phentermine–topiramate treatment was associated with significant reductions in weight, body mass index, binge-eating episode frequency, and measures of global clinical severity, eating disorder psychopathology, and obsessive-compulsive symptoms. Mean daily dose of phentermine–topiramate at endpoint was 6.8 to 41.4mg per day. The most common adverse event (AE) was dysgeusia. There were no serious AEs, and no participants displayed symptoms of medication misuse or withdrawal. Conclusion: Phentermine–topiramate could be helpful for weight loss and reduction of binge-eating symptoms in patients with obesity or overweight in addition to BED. Controlled studies are warranted.

【 授权许可】

Unknown